10/10/2019 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 10/10/2019. This eight-page document describes the Food and Drug Administration (FDA)'s approval of the marketing of a rapid diagnostic test (RDT) to detect Ebola virus antigens (proteins) in human blood from certain living individuals and samples from certain recently deceased individuals suspected to have died from Ebola (cadaveric oral fluid). The OraQuick Ebola Rapid Antigen Test is the first rapid diagnostic test the FDA has allowed to be marketed in the U.S. for Ebola virus disease (EVD). (PDF)
.png)
No hay comentarios:
Publicar un comentario